Duodenitis lansoprazole

Ogasrtro (Lansoprazole) Duodenal ulcer Gastro-oesophageal reflux Helicobacter infections 2.3 0.8 1994 - UK 1995 - US Once daily, except when used as part of combination therapy for H. pylori and for hypersectetory conditions. Twice-daily when dose >120 mg. 

Omeprazole is an antiulcer drug. It is a proton pump inhibitor. This substituted benzimidazole inhibits gastric acid secretion to help acid/peptic disorders and duodenal ulcers. It interferes with the proton pump in the mucous lining of the stomach, the last stage of acid production. It can turn off stomach acid in as little as one hour. Lansoprazole (no. 12) has a similar structure. 

Ranitidine (Zantac /GlaxoSmithKline) is a histamine H2-receptor antagonist that inhibits the release of gastric acid and is useful in the treatment of a variety of hypersecretory conditions [dyspepsia, heartburn, duodenal and gastric ulcers, and gastroesophageal reflux (GERD)]. Lansoprazole (Prevacid /TAP), omeprazole (Prilosec /AstraZeneca), and esomeprazole (Nexium /AstraZeneca) are benzimidazole... 

Lansoprazole 30 mg/day, lansoprazole 15 mg/day, and ranitidine 150 mg/day have been compared in a randomized, double-bhnd, multicenter trial in the prevention of relapse of duodenal ulcer and symptom control over 12 months in 359 patients (25). Both doses of lansoprazole were superior to ranitidine. There was no significant difference between the two lansoprazole groups, although there was a trend in favor of lansoprazole 30 mg/day. There were no differences in adverse effects profiles in the three groups. The adverse effects included diarrhea, abdominal pain, viral infections, headache, and vomiting. 

A 31 year old Japanese man with recurrent duodenal ulcer was treated with famotidine, omeprazole, and lansoprazole at different times over 3 years. Gastroscopy showed a small carcinoid tumor in the upper cardia after 35 months. The lesion became larger while the patient was taking lansoprazole. 

Bardhan KD, Crowe J, Thompson RP, Trewby PN, Keeling PN, Weir D, Crouch SL. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1999 13(6) 827-32. 

Standard PPI dosages (e.g., omeprazole 20 mg/day and lansoprazole 30 mg/day) reduce the risk of NSAID-induced gastric ulcer and duodenal ulcer. " In a large comparative multicenter trial, omeprazole 20 mg/day was superior to ranitidine 150 mg twice daily in preventing NSAID-induced gastroduodenal ulcers. Two randomized controlled trials have compared PPIs with misoprostol and placebo. 

Lazzaroni, M., Bargiggia, S., and Porro, G. B. (1997). Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pyZon-associated duodenal ulcer. Am. J. Gastroenterol. 92, 649-652. 

Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993 34 1458-1462. 

---